

## NON-GISP SUSCEPTIBILITY REPORTING

The Association of Public Health Laboratories and STD project areas were informally surveyed in 2001-2002 to identify cities or states that routinely performed antimicrobial susceptibility testing of *N. gonorrhoeae* in 2001. Information was not available for 17 of the 65 STD project areas. In 2001, no testing outside GISP occurred in 30 STD project areas: Alabama, Arkansas, Arizona, Baltimore, Colorado, Connecticut, Delaware, Idaho, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Missouri, Nevada, New Mexico, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Rhode Island, San Francisco, South Carolina, Tennessee, Vermont, Washington, D.C., Washington, or Wyoming. Information on testing in 2001 was available for 18 STD project areas (**Table 1**).

**Table 1.** Non-GISP antimicrobial susceptibility testing data for *N. gonorrhoeae* in 18 STD project areas in 2001.

Project Area	Total # Isolates	Cip S	Cip I	Cip R	Spc S	Spc R	Cfx S	Cfx DS	Cro S	Cro DS	Azi S	Azi DS <sup>a</sup>
CA												
Orange Co.	160	154	2	4	160	0	160	0	160	0	154	6
San Diego	98	96 <sup>c</sup>	0	2 <sup>c</sup>	-	-	-	-	98	0	-	-
FL	40	40	0	0	-	-	-	-	40	0	40	0
GA	244	244 <sup>c</sup>	0	0	141	0	-	-	244	0	140	0
HI	189	146	2	41	189	0	188	1	189	0	189	0
IL	45	43	1	1	45	0	44	1	45	0	44	1
Los Angeles	62	62 <sup>b</sup>	0	0	-	-	-	-	62	0	-	-
MA	386	386	0	0	386	0	-	-	386	0	-	-
MI	59	58 <sup>c</sup>	0	1 <sup>c</sup>	1	0	59	0	59	0	-	-
MN	92	92	0	0	92	0	92	0	92	0	-	-
MS	986	986	0	0	-	-	-	-	44	0	-	-
MT	13	-	-	-	13	0	-	-	12	1	-	-
NH	34	32	1	1	34	0	-	-	34	0	-	-
NJ	246	246 <sup>b</sup>	0	0	246	0	246	0	246	0	-	-
NYC	3144	3141 <sup>c</sup>	0	3 <sup>c</sup>	3144	0	-	-	3144	-	-	-
TX	83	83	0	0	-	-	-	-	83	-	-	-
UT	78	74	0	4	-	-	-	-	78	0	-	-
VA	9	9	0	0	9	0	-	-	9	0	-	-
WI	144	141	3	0	-	-	-	-	143	1	-	-
Total	6112	6033	9	57	4460	0	789	2	5168	2	567	7

Cip=ciprofloxacin; Spc=spectinomycin; Cfx=cefixime; Cro=ceftriaxone; Azi=azithromycin; S=susceptible; DS=decreased susceptibility; I=intermediate resistant; R=resistant. Cells containing only “-“ indicate that the antimicrobial for that column was not tested.

The testing methodology for all sites except Minnesota, Texas, and Florida was by disk diffusion; Minnesota, Texas, and Florida used the E-test method. Illinois used both methods.

<sup>a</sup>For this table, AziDS is defined as an isolate with azithromycin disk inhibition zone size  $\leq 30$ mm or minimum inhibitory concentration (MIC)  $\geq 1.0$ .

<sup>b</sup>Los Angeles, CA tested all isolates against levofloxacin and ciprofloxacin. New Jersey tested all isolates against ofloxacin and ciprofloxacin.

<sup>c</sup>San Diego, Georgia, Michigan, and New York City tested all isolates against ofloxacin, rather than against ciprofloxacin. The resistant isolates in Michigan and San Diego were resistant to ofloxacin.

## **Discussion**

Susceptibility data from a total of 6112 non-GISP isolates were available. Non-GISP isolates from most STD project areas do not consist of a representative or systematic sample of the gonorrhea patient population but rather a convenience sample of patients who happen to undergo culture rather than non-culture testing. In addition, in contrast to GISP, multiple non-GISP isolates from various anatomic sites may be submitted from a single patient, so the 6112 non-GISP isolates are likely to represent fewer than 6112 gonorrhea patients.

These data reveal that 0.9% (57/6099) of non-GISP isolates were resistant to ciprofloxacin or ofloxacin, which is comparable to the 0.7% (38/5472) identified for GISP isolates in 2001. Fluoroquinolone-resistant isolates were identified in California (6/320; 1.9%), Hawaii (41/189; 21.7%), Illinois (1/45; 2.2%), Michigan (1/59; 1.7%), New Hampshire (1/34; 2.9%), New York City (3/3144; 0.1%), and Utah (4/78; 5.1%).

## **Acknowledgments**

For their assistance in providing these susceptibility data, we acknowledge and thank: Orange County, CA - Paul Hannah and Karen Galliher; San Diego, CA - Nahid Mahdavi, Connie Urmeneta, and Gerry Washabaugh; FL - Ronald M. Baker; GA - Marsha Ray and Barbara Wallace; HI - Norman O'Connor; IL - Richard Zimmerman and Roman Golash; Los Angeles, CA - Leonard Lawani; MA - Al Foley; MI - Frances Pouch Downes, William Schneider, James Rudrik, and Patricia Somsel; MN - Geri Salo and Peter Carr; MS - Degen Booker; MT - Susanne Norris Zanto; NH - Peggy McSweeney; NJ - Keith Pilot; NYC - Yvonne Lue and Gladys Schlanger; TX - Bruce Elliott and Tamara Baldwin; UT - Dan Andrews; VA - Judith Carroll, Thomas York, and Barbara Hill; WI - Ajaib Singh.